JP5959617B2 - オタミキサバンの安息香酸塩 - Google Patents
オタミキサバンの安息香酸塩 Download PDFInfo
- Publication number
- JP5959617B2 JP5959617B2 JP2014501569A JP2014501569A JP5959617B2 JP 5959617 B2 JP5959617 B2 JP 5959617B2 JP 2014501569 A JP2014501569 A JP 2014501569A JP 2014501569 A JP2014501569 A JP 2014501569A JP 5959617 B2 JP5959617 B2 JP 5959617B2
- Authority
- JP
- Japan
- Prior art keywords
- benzoate
- methyl
- amino
- imino
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
- C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Description
化合物(III)の調製
化合物(V)の調製
化合物(VI)の調製
化合物(VII)の調製
溶媒添加による化合物(VIII)の調製
安息香酸塩の調製
実施例5で調製した化合物(一塩酸塩−ヘミ2−ブタノール溶媒和物)4gを熱水80mlに溶解し、固体安息香酸ナトリウム1.11gを添加することによって材料を調製した。撹拌しながら、混合物を一晩冷却した。得られた沈殿物をろ過し、水で洗浄して、減圧下に40℃で6時間乾燥した。収率は79.4%であった。
示差走査熱量測定(DSC)
Mettler DSC822e(モジュールDSC822e/700/109/414935/0025)を用いてDSC測定を実施した。密閉用の蓋とピンホールを備えた40μLアルミニウムるつぼを使用した。すべての測定は、50mL/分の窒素ガス流中、10°/分の加熱速度で実施した。測定したデータはSTARe V8.10ソフトウェアによって評価した。
結晶形態の調製
エタノール2mL中の実施例6で調製した式Iの安息香酸塩0.190gの溶液を65℃から0℃まで急速に冷却することによって結晶形態を調製した。沈殿が生じなかったので、試料を0℃で一晩放置した。沈殿物を真空ろ過によって単離し、この後減圧下に25℃で乾燥した。
動的蒸気吸着(DVS)
水分吸着/脱着等温線をSurface Measurement SystemsからのDVS−1000で記録した。2サイクルを25℃で実施し、試料を最初に乾燥窒素ガスで処理して、次に相対湿度を0%から95%まで段階的に上昇させ、この後再び0%に低下させて、試料の重量を測定した。両サイクルについての典型的な総測定時間は約20から30時間であった。
実施例5で調製したメチル(2R,3R)−2−{3−[アミノ(イミノ)メチル]ベンジル}−3−{[4−(1−オキシドピリジン−4−イル)ベンゾイル]アミノ}ブタノエ−ト一塩酸塩−ヘミ2−ブタノール溶媒和物。
示差走査熱量測定(DSC)
Mettler DSC822e(モジュールDSC822e/700/109/414935/0025)を用いてDSC測定を実施した。密閉用の蓋とピンホールを備えた40μLアルミニウムるつぼを使用した。すべての測定は、50mL/分の窒素ガス流中、10°/分の加熱速度で実施した。測定したデータはSTARe V8.10ソフトウェアによって評価した。
[実施例11]
X線粉末回折(XRPD)
X線粉末回折を、CuKα1線(波長は1.54060オングストロームである。)および線形位置敏感型検出器を用いてStoe Stadi−P透過回折計で実施した。特に明記しない限り、X線粉末回折は室温で実施した。試料は平らな標本で検討した。測定したデータを、WinXPOW V2.12ソフトウェアを用いて評価し、プロットした。
Claims (9)
- メチル(2R,3R)−2−{3−[アミノ(イミノ)メチル]ベンジル}−3−{[4−(1−オキシドピリジン−4−イル)ベンゾイル]アミノ}ブタノエ−トの安息香酸塩。
- 結晶形態または少なくとも部分的に結晶形態である、請求項1に記載の安息香酸塩。
- 前記結晶塩が、室温でCuKα1線を用いて透過法で測定したX線粉末回折パターンにおいて19.8、18.8および17.9°2θ、各々±0.2°2θで特徴的な反射を示す、請求項2に記載の安息香酸塩。
- 前記結晶塩が、室温でCuKα1線を用いて透過法で測定したX線粉末回折パターンにおいて22.0、19.8、18.8、17.9、15.7および13.6°2θ、各々±0.2°2θで特徴的な反射を示す、請求項2に記載の安息香酸塩。
- 図1に示すものと実質的に一致するX線粉末回折パターンを特徴とする、請求項2に記載の安息香酸塩。
- メチル(2R,3R)−2−{3−[アミノ(イミノ)メチル]ベンジル}−3−{[4−(1−オキシドピリジン−4−イル)ベンゾイル]アミノ}ブタノエ−トを水溶液またはアルコール水溶液中に溶解することおよび安息香酸または安息香酸ナトリウムを添加することを含む、請求項1に記載の安息香酸塩の調製方法。
- 薬物として使用するための、請求項1から5のいずれか一項に記載の安息香酸塩。
- 請求項1から5のいずれか一項に記載のメチル(2R,3R)−2−{3−[アミノ(イミノ)メチル]ベンジル}−3−{[4−(1−オキシドピリジン−4−イル)ベンゾイル]アミノ}ブタノエ−トの安息香酸塩および医薬として許容される担体または賦形剤を含む医薬組成物。
- 急性心筋梗塞、非ST上昇型心筋梗塞、不安定狭心症、血栓塞栓症、血栓溶解療法および経皮的冠動脈形成術に関連する急性血管閉塞症、一過性脳虚血発作、脳卒中、間欠性跛行および再狭窄の治療における使用のための、請求項1から5のいずれか一項に記載のメチル(2R,3R)−2−{3−[アミノ(イミノ)メチル]ベンジル}−3−{[4−(1−オキシドピリジン−4−イル)ベンゾイル]アミノ}ブタノエ−トの安息香酸塩。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305348 | 2011-03-29 | ||
EP11305348.2 | 2011-03-29 | ||
US201161500342P | 2011-06-23 | 2011-06-23 | |
US61/500,342 | 2011-06-23 | ||
PCT/EP2012/055364 WO2012130821A1 (en) | 2011-03-29 | 2012-03-27 | Benzoic acid salt of otamixaban |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014509622A JP2014509622A (ja) | 2014-04-21 |
JP2014509622A5 JP2014509622A5 (ja) | 2015-03-19 |
JP5959617B2 true JP5959617B2 (ja) | 2016-08-02 |
Family
ID=44065390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014501569A Active JP5959617B2 (ja) | 2011-03-29 | 2012-03-27 | オタミキサバンの安息香酸塩 |
Country Status (22)
Country | Link |
---|---|
US (1) | US8993602B2 (ja) |
EP (1) | EP2691371B1 (ja) |
JP (1) | JP5959617B2 (ja) |
KR (1) | KR101852226B1 (ja) |
CN (1) | CN103562183B (ja) |
AU (1) | AU2012234325B2 (ja) |
BR (1) | BR112013025105A2 (ja) |
CA (1) | CA2830965C (ja) |
CY (1) | CY1116659T1 (ja) |
DK (1) | DK2691371T3 (ja) |
ES (1) | ES2539236T3 (ja) |
HK (1) | HK1189584A1 (ja) |
HR (1) | HRP20150613T1 (ja) |
IL (1) | IL228574A (ja) |
MX (1) | MX2013011266A (ja) |
MY (1) | MY161396A (ja) |
PL (1) | PL2691371T3 (ja) |
PT (1) | PT2691371E (ja) |
RU (1) | RU2597423C2 (ja) |
SG (1) | SG193612A1 (ja) |
SI (1) | SI2691371T1 (ja) |
WO (1) | WO2012130821A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140018398A1 (en) | 2011-03-29 | 2014-01-16 | Sanofi | Otamixaban formulations with improved stability |
CN106565698B (zh) * | 2016-08-15 | 2019-03-08 | 南京帕隆材料科技有限公司 | 取代噻唑类衍生物及其制备方法和用途 |
CN106518859B (zh) * | 2016-08-15 | 2019-01-18 | 南京帕隆材料科技有限公司 | 噻唑类衍生物及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424334A (en) | 1991-12-19 | 1995-06-13 | G. D. Searle & Co. | Peptide mimetic compounds useful as platelet aggregation inhibitors |
US6080767A (en) * | 1996-01-02 | 2000-06-27 | Aventis Pharmaceuticals Products Inc. | Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides |
KR100348338B1 (ko) * | 1996-01-02 | 2003-06-02 | 아벤티스 파마슈티칼스 인크. | 치환된n-[(아미노이미노메틸또는아미노메틸)페닐]프로필아미드및이를포함하는약제학적조성물 |
GB0108903D0 (en) | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
CN101686959B (zh) * | 2007-05-02 | 2014-05-07 | 波托拉医药品公司 | 作为血小板adp受体抑制剂的化合物的组合疗法 |
MX2012000457A (es) * | 2009-07-29 | 2012-01-27 | Sanofi Sa | Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st. |
-
2012
- 2012-03-27 KR KR1020137028416A patent/KR101852226B1/ko active IP Right Grant
- 2012-03-27 MX MX2013011266A patent/MX2013011266A/es active IP Right Grant
- 2012-03-27 MY MYPI2013003459A patent/MY161396A/en unknown
- 2012-03-27 RU RU2013148005/04A patent/RU2597423C2/ru not_active IP Right Cessation
- 2012-03-27 CA CA2830965A patent/CA2830965C/en not_active Expired - Fee Related
- 2012-03-27 AU AU2012234325A patent/AU2012234325B2/en not_active Ceased
- 2012-03-27 PL PL12711858T patent/PL2691371T3/pl unknown
- 2012-03-27 DK DK12711858.6T patent/DK2691371T3/da active
- 2012-03-27 JP JP2014501569A patent/JP5959617B2/ja active Active
- 2012-03-27 BR BR112013025105A patent/BR112013025105A2/pt not_active Application Discontinuation
- 2012-03-27 PT PT127118586T patent/PT2691371E/pt unknown
- 2012-03-27 CN CN201280026534.0A patent/CN103562183B/zh active Active
- 2012-03-27 WO PCT/EP2012/055364 patent/WO2012130821A1/en active Application Filing
- 2012-03-27 SI SI201230219T patent/SI2691371T1/sl unknown
- 2012-03-27 ES ES12711858.6T patent/ES2539236T3/es active Active
- 2012-03-27 SG SG2013071766A patent/SG193612A1/en unknown
- 2012-03-27 EP EP12711858.6A patent/EP2691371B1/en active Active
- 2012-03-27 US US14/008,332 patent/US8993602B2/en active Active
-
2013
- 2013-09-29 IL IL228574A patent/IL228574A/en active IP Right Grant
-
2014
- 2014-03-17 HK HK14102611.9A patent/HK1189584A1/xx not_active IP Right Cessation
-
2015
- 2015-06-08 HR HRP20150613TT patent/HRP20150613T1/hr unknown
- 2015-06-17 CY CY20151100521T patent/CY1116659T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HK1189584A1 (en) | 2014-06-13 |
CA2830965C (en) | 2019-04-09 |
SG193612A1 (en) | 2013-11-29 |
CN103562183B (zh) | 2015-12-23 |
AU2012234325A1 (en) | 2013-10-17 |
CY1116659T1 (el) | 2017-03-15 |
MY161396A (en) | 2017-04-14 |
KR101852226B1 (ko) | 2018-04-25 |
RU2013148005A (ru) | 2015-05-10 |
PT2691371E (pt) | 2015-07-20 |
DK2691371T3 (da) | 2015-06-22 |
IL228574A (en) | 2015-07-30 |
IL228574A0 (en) | 2013-12-31 |
ES2539236T3 (es) | 2015-06-29 |
EP2691371B1 (en) | 2015-03-18 |
AU2012234325B2 (en) | 2016-08-11 |
EP2691371A1 (en) | 2014-02-05 |
WO2012130821A1 (en) | 2012-10-04 |
SI2691371T1 (sl) | 2015-07-31 |
HRP20150613T1 (hr) | 2015-07-17 |
JP2014509622A (ja) | 2014-04-21 |
US8993602B2 (en) | 2015-03-31 |
MX2013011266A (es) | 2014-03-27 |
US20140024684A1 (en) | 2014-01-23 |
KR20140022851A (ko) | 2014-02-25 |
CA2830965A1 (en) | 2012-10-04 |
CN103562183A (zh) | 2014-02-05 |
PL2691371T3 (pl) | 2015-08-31 |
BR112013025105A2 (pt) | 2017-06-06 |
RU2597423C2 (ru) | 2016-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019135258A (ja) | 第Xa因子阻害剤の結晶形態 | |
RU2709810C2 (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[3,4-с]ПИРИДИНА | |
JP5959617B2 (ja) | オタミキサバンの安息香酸塩 | |
RU2193560C2 (ru) | Новая соль | |
JP2008524228A (ja) | Xa因子阻害剤の結晶フォーム | |
JP2008514711A (ja) | ピラゾロ[3,4−c]ピリジンXA因子阻害剤の結晶フォーム | |
JP2023521411A (ja) | (9r,13s)-13-{4-[5-クロロ-2-(4-クロロ-1h-1,2,3-トリアゾール-1-イル)フェニル]-6-オキソ-1,6-ジヒドロピリミジン-1-イル}-3-(ジフルオロメチル)-9-メチル-3,4,7,15-テトラアザトリシクロ[12.3.1.02,6]オクタデカ-1(18),2(6),4,14,16-ペンタエン-8-オンの結晶体 | |
JP6317358B2 (ja) | L‐リジンを含む(3s,3s’)4,4’‐ジスルファンジイルビス(3‐アミノブタン1‐スルホン酸)の新規結晶相 | |
CA2856607C (en) | Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide | |
US9145385B2 (en) | Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid | |
US9102657B2 (en) | Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid | |
JP6357100B2 (ja) | 6−(ピペリジン−4−イルオキシ)−2h−イソキノリン−1−オン塩酸塩の結晶性溶媒和物 | |
JP2021529201A (ja) | オキシピリジンアミド誘導体の結晶形およびその調製方法 | |
EP2805705B1 (en) | Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid | |
JP2014518236A (ja) | 6−(ピペリジン−4−イルオキシ)−2h−イソキノリン−1−オン塩酸塩の多形体 | |
TW202102475A (zh) | 氧代吡啶醯胺類衍生物的晶型及製備方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150127 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150127 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150903 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151104 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20151207 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20151210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160607 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160621 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5959617 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |